Immunotherapy with checkpoint inhibitors, specifically agents targeting programmed death-1 (PD-1), are advancing in clinical trials in several gastrointestinal malignancies. At the 2017 Gastrointestinal Cancers Symposium, investigators reported encouraging findings for these agents. They noted that for the 20% to 30% of patients fortunate enough to respond, benefits can be durable.
Nivolumab in MSI-H Colorectal Cancer
In the Phase II CheckMate 142 trial, approximately 30% of 74 patients with